When the American Association for Cancer Research (AACR) launched Cancer Discovery in 2011, the field of oncology was at an inflection point. The first-generation tyrosine kinase inhibitors were demonstrating durable responses in molecularly selected patient populations, and the concept of treating cancer based on genomic alterations rather than organ of origin was gaining traction. AACR recognized that a dedicated publication channel was needed for the rapidly growing body of translational research bridging basic cancer biology with clinical application.

Over the subsequent decade and a half, Cancer Discovery has established itself as the journal where the most consequential advances in precision oncology are first reported. From the mechanistic elucidation of acquired resistance to EGFR inhibitors in lung cancer to the discovery of novel immunotherapy biomarkers and the clinical validation of KRAS G12C inhibitors, the journal’s archive reads as a chronicle of how molecularly targeted cancer medicine has evolved from promise to standard practice.

The journal’s 2025 Impact Factor of 29.5 reflects not merely citation frequency but the field’s recognition that Cancer Discovery publishes research that genuinely moves therapeutic paradigms forward. Unlike general oncology journals that publish across the full spectrum of clinical research, or basic science journals focused primarily on mechanism, Cancer Discovery occupies a distinctive niche at the intersection of molecular oncology, translational science, and early-phase clinical investigation.

The editorial mission of Cancer Discovery centers on accelerating the translation of molecular insights into therapeutic strategies. This focus has made the journal the publication venue of choice for several landmark discoveries that have directly influenced clinical practice guidelines and regulatory approvals.

Targeted Therapy Resistance Mechanisms. A substantial portion of the journal’s most-cited contributions elucidate how cancers develop resistance to molecularly targeted agents. The publication of seminal studies on EGFR T790M mutations as a resistance mechanism to first-generation EGFR inhibitors, and the subsequent characterization of C797S mutations as resistance mechanisms to third-generation osimertinib, provided the mechanistic rationale for sequential therapeutic strategies now employed in non-small cell lung cancer globally. Similarly, work published in Cancer Discovery on BRAF inhibitor resistance in melanoma—including the elucidation of MEK1 mutations, NRAS upregulation, and receptor tyrosine kinase-mediated reactivation of MAPK signaling—directly informed the development of combination BRAF/MEK inhibition protocols.

Immunotherapy Biomarkers and Mechanisms. As immune checkpoint inhibitors transformed oncology practice, Cancer Discovery emerged as a leading forum for biomarker discovery and resistance mechanism characterization. Studies identifying tumor mutational burden (TMB) as a predictive biomarker across cancer types, characterizing JAK-STAT pathway alterations as drivers of primary resistance to anti-PD-1 therapy, and elucidating the role of the gut microbiome in modulating immunotherapy response have collectively shaped how clinicians select patients for and optimize immunotherapeutic approaches.

Undruggable Target Validation. The journal has been instrumental in documenting the transition of historically “undruggable” oncogenes into viable therapeutic targets. The publication of preclinical and early clinical data on KRAS G12C inhibitors—beginning with covalent targeting strategies and progressing through Phase I trial results—exemplifies how Cancer Discovery serves as the conduit between target validation and clinical implementation. More recently, publications on KRAS G12D-targeting approaches and efforts directed at MYC, RAS family members beyond KRAS, and transcription factor complexes continue this tradition.

Liquid Biopsy and Circulating Tumor DNA. The journal has published extensively on circulating tumor DNA (ctDNA) applications in treatment monitoring, resistance detection, and minimal residual disease assessment. These studies have contributed to the regulatory acceptance of liquid biopsy companion diagnostics and the integration of ctDNA analysis into clinical trial designs across the pharmaceutical industry.

Cancer Discovery has maintained a remarkably stable citation profile relative to many high-impact journals that experience substantial year-to-year volatility. This consistency reflects both the journal’s focused editorial scope and the sustained relevance of its published content to an active research community.

Several patterns emerge from this historical trajectory. The journal’s Impact Factor increased rapidly during its first five years, rising from 10.1 in 2012 to 20.0 in 2015, as the field recognized its editorial quality and the translational relevance of its content. Since 2017, the metric has stabilized in the 26–30 range, indicating that Cancer Discovery has reached a mature citation equilibrium consistent with its position among the elite oncology journals.

The relative stability of the Impact Factor in recent years—fluctuating within approximately a 5% band since 2020—contrasts with the more dramatic declines observed at some competitor journals. This stability likely reflects the journal’s deliberate editorial strategy of publishing fewer, higher-impact articles rather than maximizing volume. Cancer Discovery publishes approximately 150–200 original research articles annually, a comparatively modest output that enables rigorous editorial selection.

From a metrics perspective, the journal’s five-year Impact Factor trend and Immediacy Index both indicate that its published research generates sustained citation activity rather than transient attention. Articles published in Cancer Discovery continue to accumulate citations over extended periods, consistent with the durable clinical relevance of translational oncology findings.

The editorial scope of Cancer Discovery is deliberately circumscribed to maintain coherence and maximize relevance to the precision oncology community. The journal publishes original research articles, reviews, and commentary in several interconnected domains:

Molecularly Targeted Therapeutics. Preclinical and clinical studies on small molecule inhibitors, antibody-drug conjugates, and other targeted agents, with emphasis on mechanism-based patient selection, resistance, and rational combination strategies. The journal prioritizes studies that include robust pharmacodynamic biomarker data and correlative science.

Cancer Genomics and Functional Genomics. Large-scale genomic characterization studies that reveal actionable therapeutic vulnerabilities, including CRISPR-based functional screens, genome-wide association studies in cancer populations, and integrative multi-omics analyses that nominate new therapeutic targets or biomarkers.

Tumor Biology and Microenvironment. Research elucidating the cellular and molecular mechanisms governing tumor initiation, progression, and metastasis, with particular emphasis on findings with demonstrable translational implications. Studies on the tumor immune microenvironment, stromal interactions, and metabolic reprogramming fall within this scope when linked to therapeutic opportunities.

Immuno-Oncology. Basic and translational investigations into cancer immunology, checkpoint inhibitor mechanisms, chimeric antigen receptor (CAR) T-cell therapies, cancer vaccines, and immune resistance pathways. The journal has published extensively on neoantigen discovery, T-cell exhaustion mechanisms, and biomarkers of immunotherapy response.

Clinical Trial Reports. Phase I and select Phase II trials that incorporate substantial correlative science, biomarker analyses, or mechanistic insights. Cancer Discovery does not typically publish straightforward efficacy trials; rather, it seeks trials that advance biological understanding alongside clinical data.

Biomarkers and Diagnostics. Studies developing and validating predictive and prognostic biomarkers, including liquid biopsy methodologies, multi-gene panel assessments, and companion diagnostic strategies integrated with therapeutic development programs.

The journal explicitly does not publish pure basic science studies without a clear translational trajectory, descriptive epidemiological research, or routine Phase III clinical trial reports. This editorial discipline maintains the journal’s distinct identity and ensures that its readership—composed predominantly of translational researchers, early-phase clinical trialists, and pharmaceutical scientists—finds consistently relevant content.

Cancer Discovery operates as the premier research journal within AACR’s portfolio of eight peer-reviewed publications, a position it has held since its founding. Understanding this portfolio context illuminates the journal’s editorial positioning and the strategic rationale behind its scope delineation.

The AACR publication hierarchy can be understood as a pyramid. At the apex stands Cancer Discovery, publishing the highest-impact translational and clinical research with the most immediate potential to influence therapeutic practice. Below it, Cancer Research serves as the broad-spectrum basic and translational research journal with a larger publication volume and correspondingly wider scope. Clinical Cancer Research focuses specifically on clinical investigations across all phases of drug development, with particular strength in later-phase trials and correlative science. The four Cancer Research Communications journals—covering basic, clinical, immuno-oncology, and precision oncology domains—provide open-access venues for high-quality research across the translational spectrum.

This portfolio structure enables AACR to offer appropriate publication venues for research at varying stages of translational maturity. A study identifying a novel oncogenic mechanism in preclinical models might first be submitted to Cancer Research; follow-up work demonstrating therapeutic vulnerability and initial clinical translation could then target Cancer Discovery; and the subsequent Phase II clinical trial with biomarker analysis might find its home in Clinical Cancer Research.

For authors, the implications are practical: Cancer Discovery represents the most selective AACR venue, with acceptance rates estimated below 10% for original research articles. The editorial standards emphasize not only scientific rigor but also the potential for clinical impact. Manuscripts are evaluated by both scientific editors and a clinical advisory panel that assesses translational relevance.

The journal’s relationship with AACR’s annual meeting programming further reinforces its translational focus. Content published in Cancer Discovery frequently originates from or is subsequently presented at AACR annual meetings, creating a symbiotic relationship between the organization’s meeting and publishing activities that accelerates the dissemination of high-priority findings.

Selecting the appropriate publication venue requires understanding how Cancer Discovery differs from its closest competitors across the translational oncology landscape. The following comparison focuses on journals that authors genuinely consider as alternatives when deciding where to submit precision oncology research.

Versus Cancer Cell. Cancer Cell and Cancer Discovery occupy similar Impact Factor strata but serve distinct research communities. Cancer Cell emphasizes fundamental cancer biology—mechanistic studies of oncogenesis, tumor suppression, and cancer cell intrinsic properties—with translational implications as a secondary consideration. In contrast, Cancer Discovery prioritizes research with demonstrated or strongly prospective clinical relevance. A study elucidating a novel signaling pathway in cancer would be more appropriate for Cancer Cell; a study leveraging that pathway to develop and validate a therapeutic strategy would align with Cancer Discovery. The journals are complementary rather than competitive, and many prominent researchers publish in both venues depending on the specific study.

Versus Cancer Research. As the broad-spectrum basic and translational research flagship of AACR, Cancer Research publishes substantially more articles annually and accepts a wider range of study types, from mechanistic cell biology to population science. Its lower Impact Factor (12.4) reflects this volume and breadth rather than any quality deficit. Authors should consider Cancer Research for well-executed studies that may not have the immediate clinical translational angle required for Cancer Discovery.

Versus Clinical Cancer Research. Clinical Cancer Research accepts a broader range of clinical trial reports, including Phase II studies with comprehensive biomarker analyses that Cancer Discovery might decline if the biological insights are incremental. The two journals have developed a collaborative relationship, with Cancer Discovery occasionally publishing companion mechanism papers to trials reported in Clinical Cancer Research.

Versus Journal of Clinical Oncology. JCO focuses on practice-changing clinical data and guideline-defining trials, with less emphasis on preclinical and mechanistic work. The higher Impact Factor reflects its position as the clinical reference standard. Authors with definitive Phase III trial results or practice-changing Phase II data should prioritize JCO; those with early-phase trials rich in correlative science or preclinical-to-clinical translation stories should consider Cancer Discovery.